JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.4
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 13, Issue 3 (2021)
Iran J War Public Health 2021, 13(3): 199-202 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2021/08/16 | Accepted: 2021/08/25 | Published: 2021/11/11
Received: 2021/08/16 | Accepted: 2021/08/25 | Published: 2021/11/11
How to cite this article
Awad W, Kadhim H, Hassan D, Al-Yassiry K. Risk of Mortality due to Sudden Hyperglycemia in COVID-19 Patients. Iran J War Public Health 2021; 13 (3) :199-202
URL: http://ijwph.ir/article-1-992-en.html
URL: http://ijwph.ir/article-1-992-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Biochemistry, College of Medicine, University of Kerbala, Kerbala, Iraq
2- Department of Physiology and Medical Physics, College of Medicine, University of Al-Ameed, Kerbala, Iraq
3- Department of Biochemistry, Health and Medical Technical College, Women University of Al-Zahraa, Kerbala, Iraq
4- Department of Pharmacology, College of Medicine, University of Kerbala, Kerbala, Iraq
2- Department of Physiology and Medical Physics, College of Medicine, University of Al-Ameed, Kerbala, Iraq
3- Department of Biochemistry, Health and Medical Technical College, Women University of Al-Zahraa, Kerbala, Iraq
4- Department of Pharmacology, College of Medicine, University of Kerbala, Kerbala, Iraq
Abstract (2271 Views)
Aims: One of the most dangerous complications of COVID-19 is sudden hyperglycemia that may carry a high incidence of the death rate. This study aimed to evaluate the relationship between death rate and hyperglycemia caused by COVID-19 infection in non-diabetic patients.
Materials & Methods: In this study, 296 patients were selected randomly, 57 patients complaining of sudden hyperglycemia (>400 mg/dl) one week after the high fever subsided; the others did not show such complain. Statistical analysis was done to evaluate the relative risk of hyperglycemia upon the incidence of mortality rate between two groups.
Findings: The X2 value was 20.5959 for all, and the p-value was not significant except for COVID-19 with hyperglycemia that showed a highly significant mortality rate (X2=15.9, p<0.001).
Conclusion: Hyperglycemia should be monitored even after regression of COVID-19 symptoms, and insulin therapy must be considered to minimize the risk of death.
Materials & Methods: In this study, 296 patients were selected randomly, 57 patients complaining of sudden hyperglycemia (>400 mg/dl) one week after the high fever subsided; the others did not show such complain. Statistical analysis was done to evaluate the relative risk of hyperglycemia upon the incidence of mortality rate between two groups.
Findings: The X2 value was 20.5959 for all, and the p-value was not significant except for COVID-19 with hyperglycemia that showed a highly significant mortality rate (X2=15.9, p<0.001).
Conclusion: Hyperglycemia should be monitored even after regression of COVID-19 symptoms, and insulin therapy must be considered to minimize the risk of death.
Keywords:
References
1. Liu J, Liu S. The management of coronavirus disease 2019 (COVID‐19). J Med Virol. 2020;92(9):1484-1490. [Link] [DOI:10.1002/jmv.25965] [PMID] [PMCID]
2. Kumar D. Corona virus: a review of COVID-19. EJMO. 4(1):8-25. [Link]
3. WHO. The corona virus disease 2019 (COVID-19). Geneva: WHO; 2020. [Link]
4. Sun Y, Koh V, Marimuthu K, Ng OT, Young B, Vasoo S, et al. Epidemiological and clinical predictors of COVID-19. Clin Infect Dis. 2020;71(15):786-92. [Link] [DOI:10.1093/cid/ciaa322] [PMID] [PMCID]
5. Zhao F, Henderson TO, Cipriano TM, Copley BL, Liu M, Burra R, et al. The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort. Cancer. 2021;127(21):4072-80. [Link] [DOI:10.1002/cncr.33798] [PMID] [PMCID]
6. Pérez-López FR, Tajada M, Savirón-Cornudella R, Sánchez-Prieto M, Chedraui P, Terán E. Coronavirus disease 2019 and gender-related mortality in European countries: A meta-analysis. Maturitas. 2020;141:59-62. [Link] [DOI:10.1016/j.maturitas.2020.06.017] [PMID] [PMCID]
7. Dehghanbanadaki H, Seif F, Vahidi Y, Razi F, Hashemi E, Khoshmirsafa M, et al . Bibliometric analysis of global scientific research on Coronavirus (COVID-19). Med J Islam Repub Iran. 2020;34(1):354-62. [Link] [DOI:10.47176/mjiri.34.51]
8. Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020;24(6):3404-10. [Link]
9. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res. 2020;7(1):1-10. [Link] [DOI:10.1186/s40779-020-00240-0] [PMID] [PMCID]
10. Yulia H. Online learning to prevent the spread of pandemic corona virus in Indonesia. ETERNAL. 2020;11(1). [Link] [DOI:10.26877/eternal.v11i1.6068]
11. Dietz W, Santos‐Burgoa C. Obesity and its implications for COVID‐19 mortality. Obesity. 2020;28(6):1005. [Link] [DOI:10.1002/oby.22818] [PMID]
12. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020 Mar:270. [Link] [DOI:10.1093/cid/ciaa270] [PMID] [PMCID]
13. Kakodkar P, Kaka N, Baig MN. A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19). Cureus. 2020;12(4):7560. [Link] [DOI:10.7759/cureus.7560] [PMID] [PMCID]
14. Coppelli A, Giannarelli R, Aragona M, Penno G, Falcone M, Tiseo G, et al. Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: The Pisa COVID-19 study. Diabetes Care. 2020;43(10):2345-8. [Link] [DOI:10.2337/dc20-1380] [PMID]
15. Ceriello A. Hyperglycemia and the worse prognosis of COVID-19. Why a fast blood glucose control should be mandatory. Diabetes Res Clin Pract. 2020;163:108186. [Link] [DOI:10.1016/j.diabres.2020.108186] [PMID] [PMCID]
16. Mirzaei F, Khodadadi I, Vafaei SA, Abbasi-Oshaghi E, TayebiniaH, Farahani F. Importance of hyperglycemia in COVID-19 intensive-care patients: Mechanism and treatment strategy. Prim Care Diabetes. 2021;15(3):409-416. [Link] [DOI:10.1016/j.pcd.2021.01.002] [PMID] [PMCID]
17. Bellido V, Pérez A. Inpatient hyperglycemia management and COVID-19. Diabetes Ther. 2021;12(1):121-132. [Link] [DOI:10.1007/s13300-020-00966-z] [PMID] [PMCID]
18. Kasuki L, Gadelha MR. Letter to the Editor: "Our Response to COVID-19 as Endocrinologists and Diabetologists". J Clin Endocrinol Metab. 2020;105(7):dgaa224. [Link] [DOI:10.1210/clinem/dgaa224] [PMID] [PMCID]
19. Cun Y, Li C, Shi L, Sun M, Dai S, Sun L, et al. COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A,-B,-C) across global populations. Hum Vaccin Immunother. 2021;17(4):1097-1108. [Link] [DOI:10.1080/21645515.2020.1823777] [PMID] [PMCID]
20. Landayan RP, Saint-Felix S, Williams A. Probable Interaction Between Warfarin and the Combination of Remdesivir With Dexamethasone for Coronavirus Disease 2019 (COVID-19) Treatment: A 2 Case Report. J Pharm Pract. 2021;8971900211008623. [Link] [DOI:10.1177/08971900211008623] [PMID]
21. Gianchandani R, Esfandiari NH, Ang L, Iyengar J, Knotts S, Choksi P, et al. Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes. 2020;69(10):2048-53. [Link] [DOI:10.2337/dbi20-0022] [PMID]
22. Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res Clin Pract. 2020;167:108382. [Link] [DOI:10.1016/j.diabres.2020.108382] [PMID] [PMCID]
23. Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID‐19 pandemic. J Med Virol. 2020;92(7):770-5. [Link] [DOI:10.1002/jmv.25887] [PMID] [PMCID]
24. Siddiqui RS , Zirkiyeva M, Saliaj M. Onset of ketosis-prone diabetes in the setting of COVID-19 infection. Cureus. 2020;12(10):e10779. [Link] [DOI:10.7759/cureus.10779]
25. Jacobson J, Antony K, Beninati M, Alward W, Hoppe KK. Use of dexamethasone, remdesivir, convalescent plasma and prone positioning in the treatment of severe COVID-19 infection in pregnancy: A case report. Case Rep Womens Health. 2021;29:e00273. [Link] [DOI:10.1016/j.crwh.2020.e00273] [PMID] [PMCID]
26. Dehghani Firoozabadi A, Shojaei Andebili S, Sabbaghi Mehrjardi MA, Sheikhha MH, Haghparast A. Analysis of Toll like Receptor2 &4 (TLR2 & TLR4) Expression in Testis Tissue of Wistar Rats with Induced Hyperglycemia. 4th Yazd International Congress and student Award in Reproductive Medicine , 2011-04-15. Mashahd: Ferdowsi university; 2011. [Persian] [Link]